0:38

Sri Armugam and team at Emery Pharma walk through MIC testing, which measures how much antimicrobial drug stops bacterial growth. The demo uses a 96-well plate with two-fold serial dilutions of the drug, a Staphylococcus aureus strain adjusted to 0.5 McFarland, and 18 to 20 hours of incubation at 37°C. They read the result with a mirror and spectrophotometer to find where growth stops.

Questions this video answers

0.5 McFarland turbidity standard

18–20 hours at 37 degrees Celsius

Test article at 2× concentration

Columns 2–11

Column 12

More from Dr.

youtube.com

Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health

11mo ago
youtube.com

Robert Lustig, MD: Everything You Know About Obesity Is Wrong

11mo ago
youtube.com

What is the latest on Ozempic and Ozempic like drugs #ozempic #glp1

11mo ago
youtube.com

Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It

11mo ago
youtu.be

Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.

11mo ago
youtube.com

The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig

11mo ago
youtube.com

Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet

1y ago
youtube.com

Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome

1y ago
youtube.com

Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose

1y ago
youtube.com

Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance

1y ago
youtube.com

Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet

1y ago
See all content